



**First Patient Case Treated with myQA Patients, part of IBA's new myQA®
Global quality assurance Platform for the Treatment of Cancer**

myQA is a unique platform that connects QA applications, people, and know-how through a Central Database and the Cloud.

Bartlett, TN, July 8, 2015 – IBA (Ion Beam Applications S.A.), the global high-tech leader in the next generation of radiation therapy solutions and radiation therapy dosimetry for the treatment of cancer, announces that the first patient case in the United States has successfully been quality controlled using myQA Global QA Platform at the LewisGale Regional Center in Pulaski, Virginia. This is a significant milestone for IBA and major step forward in the safe treatment of cancer.

The first of its kind platform-based plan verification offers distinct advantages such as having the software installed on a database. In contrast to local installation, this means data can be accessed anywhere, anytime connecting staff and treatment locations.

“With SQL server capability, myQA can be installed directly into a center’s network and back up can be performed daily by IS. Data loss is one more thing I don’t have to worry about,” said James Nunn, Senior Medical Physicist at LewisGale. “Through the web interface, I am updated about all my QA status in real-time. Overall, myQA has been well-received by our therapists and physics team who use it for plan QA as well as morning QA. We use myQA for our end-of-day checks, CT QA in the software, and we are expanding to other areas in the department.”

“Another key benefit of having your plan verification software on a global QA platform is that you can review the complete status of all your patient QA using myQA Cockpit, anywhere at any time,” says Timo Hausbeck, PhD, PV Product Manager at IBA Dosimetry. “You can now have full control of your patient data and never miss any QA task or incident.”





About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1100 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

Media Contact:

Suzanne Shankle
Marketing Specialist
IBA Dosimetry
3150 Stage Post Drive, Suite 110
Bartlett, TN 38133
Tel: (901) 386-2242
Suzanne.shankle@iba-group.com

<http://www.iba-dosimetry.com>

Press release | **July 8, 2015**

###